Opyl Ltd. Advises Investor Caution and Diligence
Opyl Ltd Announces Director's Final Interests
Opyl Ltd. Advances AI Platform and Streamlines Business
Opyl Ltd. Calls for Virtual General Meeting
Opyl Expands TrialKey Coverage; Shares Up 38%
Digital health company Opyl (ASX:OPL) expanded its TrialKey.ai platform, increasing its coverage to 350,000 trials from 65,000 and enhancing its ability to predict and optimize clinical research and d
Opyl to Divest Opin Business
Opyl (ASX:OPL) signed a binding sale and purchase agreement to divest its Opin business, allowing the company to focus on high-growth, artificial intelligence-related ventures, according to a Tuesday
Opyl Divests Subsidiary Opin to Focus on Development of AI Clinical Trial Platform
Opyl (ASX: OPL) will divest its clinical trial recruitment subsidiary Opin to an entity controlled by global health technology entrepreneur Dr Hugo Stephenson.
Opyl Receives Offer for Patient Recruitment Business
Opyl (ASX:OPL) received a non-binding offer to acquire its patient candidate recruitment business, Opin, from Trial Screen for AU$1 and 20% of the equity in Trial Screen. Trial Screen is an entity con
Opyl Requests Trading Halt After Receiving Offer For Opin Business
Opyl (ASX:OPL) requested a halt in the trading of its securities Wednesday afternoon after receiving a non-binding offer to acquire the company's Opin business, according to a same-day filing with the
Opyl Chair Stepping Down in End-April
Opyl (ASX:OPL) said Mark Ziirsen will step down as nonexecutive chair, effective April 30. Ziirsen joined the company's board in September 2020 and started serving as chair in August 2022, according t
Opyl Raises Nearly AU$900,000 From Rights Issue Shortfall Placement
Opyl (ASX:OPL) raised AU$886,200 from the successful placement of a rights issue shortfall. This brought the total funds raised from the rights offer to about AU$1.4 million through the issue of 47,77
Opyl Receives Commitments for Potential Shortfall
Opyl (ASX:OPL) received commitments for any potential remaining shortfall under the current nonrenounceable rights issue offer to raise up to AU$1.4 million. Including the recent AU$580,000 placement,
Opyl Appoints Interim CEO
Digital health company Opyl (ASX:OPL) appointed Saurabh Jain as interim chief executive, effective Friday. Jain recently joined the Spacetalk (ASX:SPA) board where he stepped into the role of acting C
Opyl Secures R&D Tax Rebate for Fiscal Year 2023
Opyl (ASX:OPL) secured a tax rebate worth AU$530,580 for the fiscal year ended June 30 from the Australian government's research and development tax incentive scheme, the medical technology firm said
Opyl (ASX:OPL) Enters MSA and Secures Recruitment Contracts With Bristol Myers Squibb
No Data